Wondfo Biotech released its 2026 interim report, with net profit attributable to the parent company at 123 million yuan, down 35.24% from the same period last year. Total operating revenue was 1.039 billion yuan, down 16.63% year-on-year. Net cash inflow from operating activities was 424 million yuan. The latest gross margin was 63.53%, ROE was 2.25%, and diluted earnings per share was 0.26 yuan. The company had 40,400 shareholders, and the top ten shareholders held 47.61% of the total share capital.
Guangzhou Wondfo Biotech Co LtdNet profit fell 35.24% and revenue dropped 16.63% in the interim report.
